Cystatin C signal transduction chromogenic detection method based on aptamer modified human chorionic gonadotropin and chromogenic kit

Through the signal transduction chromatogen-modified human villus gonadotropin based on aptamers, the problem of low-concentration cystatin C detection in serum is solved, and rapid, simple and high-sensitivity detection is achieved, suitable for early renal function Diagnosis and monitoring of injury.

CN119044504APending Publication Date: 2024-11-29XI AN JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411153381.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art cannot effectively realize the rapid, simple and highly sensitive detection of low-concentration cystatin C in serum, limiting the diagnosis and monitoring of early renal function injury.

Method used

Using aptamer-modified human villous gonadotropin signal transduction and color development detection method, the detection of CysC is achieved through enzymatic lysis, blocking and color development reactions, including enzymatic lysis solution, blocking solution and Specific aptamers modify the HCG solution to form a stable CysC-HCG-aplastomer complex and undergo a chromogenic reaction to detect the CysC concentration.

Benefits of technology

It realizes fast, simple and highly sensitive CysC detection without complex instruments, improves the specificity and accuracy of the detection, is suitable for on-site diagnosis and large-scale screening, reduces the false positive rate, and provides intuitive detection results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119044504A_ABST
    Figure CN119044504A_ABST
Patent Text Reader

Abstract

The invention discloses a cystatin C (CysC) signal transduction chromogenic detection method based on aptamer modified human chorionic gonadotropin (HCG) and a chromogenic kit, and belongs to the technical field of biomedical detection.According to the method, specific interaction between the aptamer modified human chorionic gonadotropin (HCG) and the CysC, between the aptamer modified human chorionic gonadotropin (HCG) and pawpaw hydrolase and between the aptamer modified human chorionic gonadotropin (HCG) and bovine serum albumin (BSA) is utilized; the rapid, sensitive and accurate qualitative detection of CysC is realized through the color change of the HCG gold-labeled detection card. According to the method, complex operation or high-end equipment is not needed, a result can be visually read by using an HCG gold label card after a sample and a specific solution are simply mixed, the detection threshold is greatly reduced, the convenience and accessibility of CysC detection are improved, a simpler and more effective self-screening and monitoring means is provided for renal function evaluation, and the method is suitable for clinical application. The method is of great significance to early discovery and management of patients with renal function impairment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a biochemical marker colorimetric detection technology, in particular to a cystatin C signal transduction colorimetric detection method and a colorimetric kit based on aptamer-modified human chorionic gonadotropin. Background Art

[0002] Cystatin C (CysC), also known as cysteine ​​protease inhibitor C, is a low molecular weight, non-glycosylated basic protein composed of 120 amino acids. CysC in the human body is produced by eukaryotic cells at a constant rate and released into the blood. It is freely filtered through the glomerulus and finally reabsorbed and metabolically decomposed in the proximal tubule, and no longer returns to the blood circulation. Existing studies have shown that when the patient's glomerular filtration rate (GFR) decreases, the serum CysC concentration will increase before serum creatinine (Scr) and urea nitrogen (BUN), that is, CysC is a more sensitive biochemical marker of renal function damage than Scr and BUN. Therefore, real-time detection of changes in the patient's CysC concentration is of great significance for the early diagnosis of renal function damage caused by various diseases such as diabetes, hypertension, and kidney transplantation.

[0003] Since the serum concentration of CysC is low, in order to realize its clinical application value, highly sensitive CysC detection methods have been continuously developed in recent years. Existing CysC detection methods include unidirectional immunodiffusion, radiometric determination, fluorescence determination, enzyme-linked immunosorbent assay, and latex particle enhanced immunoturbidimetry. However, these methods still have shortcomings such as complex operation, long time consumption, and the need for precision analytical instruments to assist in detection. Therefore, it is urgent to develop a simple, rapid, and highly sensitive CysC concentration detection method that does not require additional equipment to meet the needs of early screening, diagnosis, and monitoring of renal function damage caused by various diseases.

[0004] Gold Label rapid test card has the advantages of convenient operation, no need for professional operation and precision instruments, and fast detection process, and is widely used in the instant detection of various biochemical markers. Researchers have found that based on commercial human chorionic gonadotropin (HCG) pregnancy test strips, by constructing different targeted-HCG signal transduction processes, it is possible to effectively achieve colorimetric detection of various non-HCG substances such as lysozyme, chloramphenicol, and DNA. However, due to the significant differences in structure and function between CysC and HCG, the existing HCG test strips cannot be directly used for colorimetric detection of CysC. As a sensitive indicator of early renal insufficiency, CysC has a low concentration in serum and requires a high-precision detection method to accurately measure it. The colorimetric detection method based on HCG test strips cannot meet the sensitivity and specificity requirements of CysC detection. This method has not yet been applied to the colorimetric detection of low-concentration CysC in serum, which limits its application in self-screening and detection of patients with early renal impairment. Summary of the invention

[0005] In view of the low concentration of CysC in serum, the technical status quo that traditional detection methods have complex operation steps, are time-consuming and rely on precision instruments, which is not conducive to widespread popularization and instant detection, the present invention aims to provide a CysC signal transduction colorimetric detection method and a colorimetric kit based on aptamer-modified HCG.

[0006] In order to achieve the above object, the present invention has formulated the following technical scheme:

[0007] The present invention provides a non-disease diagnosis method for chromogenic detection of cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin, comprising:

[0008] The test sample containing CysC is mixed with enzymolysis solution C for enzymolysis reaction to obtain a reaction solution after enzymolysis; a blocking solution B containing BSA molecules is added to the reaction solution after enzymolysis to block non-specific binding sites to obtain a blocked mixed solution; a solution A containing aptamer-modified HCG capable of specifically recognizing and binding to CysC is added to the blocked mixed solution to react and form a reaction solution containing a stable CysC-HCG-aptamer complex; the HCG gold-labeled rapid detection card is immersed in the reaction solution, and the CysC detection of the test sample is achieved through a color development reaction.

[0009] The volume ratio of the enzymatic hydrolysate C to the sample containing CysC to be tested is 1:10, and the enzymatic hydrolysis reaction conditions are standing at room temperature for 20 to 40 minutes.

[0010] The volume ratio of the blocking solution B to the blocking solution C is 8 to 15:1, and the blocking condition is incubation at room temperature for 20 to 40 minutes.

[0011] Furthermore, the sealing liquid B is obtained by mixing the graphene oxide dispersion and the BSA solution in a volume ratio of 1:1.

[0012] The volume ratio of the added amount of the A solution to the C solution is 8 to 15:1, and the reaction condition for forming a stable CysC-HCG-aptamer complex is room temperature reaction for 20 to 40 minutes.

[0013] Furthermore, the A solution: HCG solution and sulfo-SMCC solution are reacted in a volume ratio of 20:1 to obtain a coordination product, which is purified to obtain an activated HCG solution; TCEP solution and PBS buffer solution are added to the thiolated BSA aptamer solution in a volume ratio of 4:25:100 and incubated at room temperature for 20 minutes to 40 minutes to obtain a thiolated BSA aptamer solution; the activated HCG solution and the thiolated BSA aptamer solution are mixed in a volume ratio of 21:5 and incubated at room temperature for 1 hour to 3 hours, and impurities are removed to obtain a BSA aptamer-modified HCG high-concentration mother solution, which is diluted to obtain A solution.

[0014] The HCG gold-labeled rapid test card is immersed in the reaction solution for 1 to 3 minutes.

[0015] The invention provides a colorimetric kit for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin. The colorimetric kit comprises an enzymatic hydrolysis liquid C for enzymatically hydrolyzing a sample to be tested containing CysC, a blocking liquid B for blocking non-specific binding sites, a liquid A capable of specifically recognizing and binding to CysC, and an HCG gold-labeled rapid detection card for realizing a colorimetric reaction. After the enzymatic hydrolysis liquid C enzymatically hydrolyzes the sample to be tested containing CysC, the blocking liquid B blocks the non-specific binding sites, the liquid A contains an aptamer-modified HCG capable of specifically recognizing and binding to CysC, and can specifically recognize and bind to CysC, and a stable CysC-HCG-aptamer complex is formed by reaction. The HCG gold-labeled rapid detection card receives the signal of the CysC-HCG-aptamer complex, and intuitively displays the detection result through a colorimetric reaction.

[0016] The enzymolysis solution C is a papaya hydrolase solution.

[0017] Furthermore, the enzymatic hydrolyzate C is a papaya hydrolase solution with a molar concentration of 10 μg / mL to 20 μg / mL.

[0018] Furthermore, the solvent of the papaya hydrolase solution is a mixed solution containing disodium ethylenediaminetetraacetic acid with a molar concentration of 40 mmol / L, Na2HPO4 with a molar concentration of 50 mmol / L, and L-cysteine ​​with a molar concentration of 50 mmol / L.

[0019] The sealing liquid B comprises a graphene oxide dispersion and a BSA solution.

[0020] Furthermore, the molar concentration of the graphene oxide dispersion is 0.1 mg / mL to 0.5 mg / mL, and the molar concentration of the BSA solution is 0.03 mg / mL to 0.07 mg / mL.

[0021] Furthermore, the solvent of the graphene oxide dispersion is a HEPES buffer with a molar concentration of 25 mmol / L, the HEPES buffer has a pH of 7.2, and contains NaCl with a molar concentration of 0.1 mol / L, MgCl2 with a molar concentration of 5 mmol / L, and KCl with a molar concentration of 25 mmol / L.

[0022] The solution A includes HCG solution, sulfo-SMCC solution, and thiolated bovine serum albumin aptamer solution; the sequence of the thiolated bovine serum albumin aptamer is shown in SEIQ NO:1.

[0023] Furthermore, the molar concentration of the HCG solution is 1 μmol / L to 8 μmol / L, the molar concentration of the sulfo-SMCC solution is 1 mmol / L to 6 mmol / L, and the molar concentration of the thiolated bovine serum albumin aptamer solution is 5 μmol / L to 20 μmol / L.

[0024] Furthermore, the solvent of the HCG solution is a PBS buffer with a molar concentration of 0.1 mol / L, the PBS buffer has a pH of 7.2, and contains NaCl with a molar concentration of 0.1 mol / L; the solvent of the sulfo-SMCC solution is deionized water.

[0025] At the same time, the present invention provides the use of the above-mentioned chromogenic kit for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin in serum CysC chromogenic detection.

[0026] Compared with the prior art, the present invention achieves the following technical effects:

[0027] The present invention provides a non-disease diagnosis method for cystatin C signal transduction colorimetric detection based on aptamer-modified human chorionic gonadotropin. The entire detection method includes enzymatic hydrolysis reaction, blocking non-specific binding sites, forming CysC-HCG-aptamer complex, and signal transduction and colorimetric reaction. The operation is simple and easy, and can be performed without complex instruments and equipment. It can be completed in a short time and is suitable for on-site rapid detection and diagnosis. The aptamer-modified HCG is used as a recognition element. The aptamer can specifically recognize and bind to CysC, which ensures the high selectivity of the detection method for CysC and avoids The interference of non-specific binding is avoided, thereby improving the sensitivity of detection; after the enzymatic hydrolysis reaction, by adding the blocking solution B, the possible non-specific binding sites are effectively blocked, and the specificity of detection is further improved; the CysC-HCG-aptamer complex formed after CysC is combined with the aptamer-modified HCG realizes signal amplification through the introduction of HCG, so that the detection limit of the detection method for CysC is lower, and the sensitivity of detection is improved; the sensitivity of the color development reaction ensures the accuracy of the detection result, and the method of the present invention has broad application prospects in the detection of CysC.

[0028] Furthermore, the volume ratio of enzymatic hydrolyzate C to the sample containing CysC to be tested and the enzymatic hydrolysis reaction conditions were clarified to ensure the effective release of CysC and improve the sensitivity and accuracy of the detection; by adjusting the addition amount of blocking liquid B and the blocking conditions, the nonspecific binding was effectively reduced, the specificity of the detection was improved, and the false positive rate was reduced; the addition amount of liquid A and the conditions for the formation of the CysC-HCG-aptamer complex were optimized to ensure the stable formation of the complex, further improving the sensitivity and reliability of the detection; the time for the HCG gold label rapid detection card to be immersed in the reaction liquid ensured the full progress of the color development reaction, while avoiding excessive or unstable color changes caused by too long a time; by activating HCG, preparing thiol-BSA aptamers and the combination process of the two, a guarantee was provided for obtaining a highly specific detection reagent; a mixture of graphene oxide dispersion and BSA solution was used as the blocking liquid B, and the nano effect of graphene oxide helped to further improve the blocking effect, reduce nonspecific binding, and improve the detection accuracy.

[0029] The present invention provides a chromogenic kit for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin, comprising an enzymatic hydrolysis solution C, a blocking solution B, a solution A and an HCG gold-labeled rapid detection card. The entire detection process of the kit includes enzymatic hydrolysis, blocking, specific recognition and color development reaction, and the reaction time is short, so that rapid detection of CysC can be achieved; all necessary detection reagents are integrated, which is convenient for user operation and improves the convenience and reliability of detection; the HCG gold-labeled rapid detection card intuitively displays the detection results through the color development reaction, and the user can quickly judge the concentration level of CysC according to the color change, without the need for additional instruments to analyze the results, and the color development reaction has high stability and repeatability, thereby ensuring the reliability of the detection results. The kit is suitable for large-scale screening and use by primary medical institutions, and is helpful to promote the balanced allocation of medical resources and the popularization of medical services.

[0030] Furthermore, papaya hydrolase is used as the enzymatic solution C, which has efficient and specific enzymatic hydrolysis ability, can effectively release CysC, improve the sensitivity of detection, and can accurately detect it through signal transduction and color development reaction even when the CysC concentration is low; the blocking solution B contains graphene oxide dispersion and BSA solution, and utilizes the nano effect of graphene oxide and the blocking effect of BSA to effectively reduce nonspecific binding and improve the specificity of detection; the HCG solution, sulfo-SMCC solution and thiolated bovine serum albumin aptamer solution in the A solution form aptamer-modified HCG through specific chemical reactions, which can specifically recognize and bind to CysC, thereby improving the accuracy and sensitivity of detection; at the same time, the sequence specificity of the aptamer ensures the high selectivity of the detection; the use of the HCG gold label rapid test card makes the test results intuitive and easy to read, and the user only needs to observe the color change on the test card to determine the presence or absence of CysC in the test sample, without the need for complex instruments or professional knowledge.

[0031] The application of the colorimetric kit provided by the present invention in the colorimetric detection of serum CysC provides a rapid, accurate and reliable CysC detection method for clinical use. CysC is an important indicator for renal function assessment, cardiovascular disease risk assessment, etc., and its accurate detection is of great significance for the early diagnosis and treatment of diseases. Therefore, the application of the kit has broad clinical value and social significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 The figure is a schematic diagram of the preparation of liquid A, liquid B and liquid C in the colorimetric kit for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin of the present invention; wherein, 1 is HCG; 2 is sulfo-SMCC; 3 is thiolated BSA aptamer; 4 is liquid A; 5 is a monolayer of graphene oxide; 6 is a BSA molecule; 7 is liquid C;

[0033] Figure 2 Schematic diagram of the principle of the chromogenic detection method of cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin of the present invention, wherein 8 is a human serum simulation fluid sample containing non-CysC substances, 9 is a human serum simulation fluid sample containing CysC, 10 is a polypeptide, and 11 is an HCG gold-labeled rapid detection card. DETAILED DESCRIPTION

[0034] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0035] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0036] Example 1

[0037] The present invention provides a chromogenic detection method for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin, wherein the CysC signal transduction chromogenic kit comprises: aptamer-modified HCG 4 (liquid A) generated by cross-linking HCG1, 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid sulfonic acid succinimidyl ester sodium salt (sulfo-SMCC) 2 and thiolated BSA aptamer 3; a mixed solution (liquid B) of monolayer graphene oxide 5 and BSA molecules 6; a papain hydrolase 7 solution (liquid C) and a commercial HCG gold-labeled rapid detection card 11.

[0038] The HCG1, sulfo-SMCC 2 and thiolated BSA aptamer 3 are all in solution state, and the specific solvents and solute concentrations are as follows: the solvent of the HCG solution is 0.1mol / L PBS buffer (containing 0.1mol / LNaCl, pH=7.2), and the concentration is 2μmol / L; the solvent of the sulfo-SMCC solution is deionized water, and the concentration is 1mmol / L; the sequence of the thiolated BSA aptamer is: 5'-HS-GTATCGAGCGCAGGGGCGCCTTTGTTAATGATTACGGGCG-3', and the concentration is 10μmol / L. The preparation method of the A solution is as follows: 100 μL HCG solution and 5 μL sulfo-SMCC solution are mixed at room temperature and slightly shaken for 1 hour to achieve coordination bonding between HCG and sulfo-SMCC; then the coordination product is purified using 0.1 mol / L PBS buffer (containing 0.1 mol / L NaCl, pH=6.8) and an Amicon-10 K ultrafiltration tube to remove unpaired components. At the same time, 0.8 μL 1mmol / L tri(2-carboxyethyl)phosphine (TCEP) solution and 5 μL 0.01mol / L PBS buffer (pH=5.5) were added to 20 μL thiolated BSA aptamer solution, stirred and incubated at room temperature for 30 min to reduce the formation of disulfide bonds between aptamers; the above activated HCG solution and thiolated BSA aptamer solution were mixed at a ratio of 21:5 and incubated at room temperature for 2 h, and then the unreacted aptamer was removed using an Amicon-30 K ultrafiltration tube to obtain a high-concentration mother solution of BSA aptamer-modified HCG. The high-concentration mother solution was diluted to 100 μL to finally obtain the target A solution, which was stored at 4°C.

[0039] The graphene oxide 5 is a dispersion, the solvent of which is a 25mmol / L 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) buffer (containing 0.1mol NaCl, 5mmol / L MgCl2, 25mmol / L KCl, pH=7.2), the graphene oxide concentration is 0.2mg / ml, and the morphology of the graphene oxide needs to be a single layer and the average area reaches the micron level; the solvent of the BSA molecule 6 solution is a HEPES buffer (the same as above) and the concentration is 0.1mg / mL; the graphene oxide dispersion and the BSA molecule solution are mixed in a volume ratio of 1:1, and finally the B solution is obtained, in which the concentrations of graphene oxide and BSA are 0.1 and 0.05mg / mL, respectively.

[0040] The solvent of the papain hydrolase 7 solution (liquid C) is a mixed solution of 40mmol / L disodium ethylenediaminetetraacetate (EDTA-Na2), 50mmol / LNa2HPO4 and 50mmol / L L-cysteine, and the concentration of papain hydrolase is 15μg / mL.

[0041] Take 10 μL of human serum simulation samples to be tested, one group of human serum simulation samples contains non-CysC substance 8, and the other group of human serum simulation samples contains CysC9, add 1 μL of C solution and incubate for 30 minutes; then continue to add 10 μL of B solution to the mixed solution after incubation and incubate for 30 minutes; finally, add 10 μL of A solution to the above solution again, mix well and incubate for 30 minutes; take the HCG gold label rapid test card and immerse it in the incubated mixed solution, take it out after 2 minutes to read the color development result of the HCG gold label rapid test card, the color development result is shown in the attached Figure 2 shown.

[0042] By the attached Figure 2 It can be seen that in the experimental group without CysC human serum simulation solution, the activity of papain hydrolase 7 could not be inhibited; under the action of papain hydrolase 7, BSA molecule 6 was hydrolyzed into polypeptide 10, which caused a large amount of aptamer-modified HCG4 to be adsorbed on graphene oxide 5, and finally the color development result of HCG test paper 11 was negative (N); in the experimental group with CysC human serum simulation solution, the hydrolysis activity of papain hydrolase 7 was inhibited, and BSA molecule 6 was retained and specifically bound to the aptamer structure on the modified HCG4, resulting in a change in the spatial structure of the aptamer, which significantly reduced the adsorption of graphene oxide 5 on the aptamer-modified HCG4, so the color development result on HCG test paper 11 was positive (P).

[0043] Combined with Figure 2The principle of the present invention is that CysC molecule 9 has a specific affinity with papain hydrolase 7. When the N-terminal site of CysC molecule 9 binds to the catalytic center of papain hydrolase 7, the hydrolysis of papain hydrolase 7 is significantly inhibited. Therefore, when the test solution contains CysC molecule 9, papain hydrolase 7 in solution C cannot effectively hydrolyze BSA molecule 6 in solution B, so that BSA molecule 6 in the mixed solution is retained. When solution A is added, the unhydrolyzed BSA molecule 6 specifically binds to the aptamer structure on the modified HCG 4, resulting in a change in the spatial structure of the aptamer, thereby significantly reducing the adsorption of graphene oxide 5 on the aptamer-modified HCG 4. At this time, the aptamer-modified HCG combined with BSA is in a free state in the solution, which can cause the HCG test paper 11 to have a positive (P) color development reaction, such as Figure 2 On the contrary, when the test solution contains non-CysC substance 8, it cannot specifically bind to papain hydrolase 7, so the hydrolysis of papain hydrolase 7 is retained, and the BSA molecule 6 in solution B is hydrolyzed into polypeptide 10, which loses the effect of changing the spatial structure of the aptamer on the modified HCG 4, causing the aptamer-modified HCG 4 to be adsorbed on the graphene oxide 5 in large quantities, that is, it is in a non-free state in the solution, making the test result of HCG test paper 11 negative (N), as shown. Figure 2 Left side.

[0044] Example 2

[0045] Based on Example 1, this example provides a colorimetric detection method for CysC signal transduction based on aptamer-modified HCG, wherein 10 μL of human serum simulation fluid samples to be tested are taken respectively, one group of which contains non-CysC substances and the other group of which contains CysC substances. 1 μL of C solution is added to each of them and incubated for 30 minutes; then 8 μL of B solution is added to the mixed solution after incubation and incubated for 30 minutes; finally, 15 μL of A solution is added to the above solution again, mixed thoroughly and incubated for 30 minutes; an HCG gold-labeled rapid test card is taken and immersed in the incubated mixed solution, and after 2 minutes, the colorimetric result of the HCG gold-labeled rapid test card is taken out and read; the colorimetric result on the HCG test paper of the human serum simulation fluid sample containing CysC is positive, and the colorimetric result on the HCG test paper of the human serum simulation fluid sample containing non-CysC is negative.

[0046] Example 3

[0047] This example provides a CysC signal transduction color development kit based on Example 1, wherein the kit contains:

[0048] Solution A includes a HCG solution with a concentration of 6 μmol / L, a sulfo-SMCC solution with a concentration of 3 mmol / L, and a thiolated BSA aptamer solution with a concentration of 15 μmol / L. Solution A is prepared by: the volume ratio of the HCG solution to the sulfo-SMCC solution is 20:1, and the reaction conditions are room temperature for 1 hour; the volume ratio of the TCEP solution, PBS buffer and the thiolated BSA aptamer solution is 4:25:100, and the reaction is incubated at room temperature for 30 minutes; the volume ratio of the activated HCG solution to the thiolated BSA aptamer solution is 21:5, and the reaction is incubated at room temperature for 2 hours;

[0049] Liquid B includes a graphene oxide dispersion with a concentration of 0.3 mg / mL and a BSA solution with a concentration of 0.04 mg / mL; Liquid B is prepared by: the volume ratio of the graphene oxide dispersion to the BSA molecular solution is 1:1.

[0050] Solution C: papain hydrolase solution with a concentration of 10 μg / mL.

[0051] Take 10 μL of human serum simulation fluid samples to be tested respectively, one group of human serum simulation fluid samples contains non-CysC substances, and the other group of human serum simulation fluid samples contains CysC, add 1 μL of C solution respectively and incubate for 30 minutes; then continue to add 10 μL of B solution to the mixed solution after incubation and incubate for 30 minutes; finally, add 10 μL of A solution to the above solution again, mix thoroughly and incubate for 30 minutes; take the HCG gold-labeled rapid test card and immerse it in the incubated mixed solution, take it out after 2 minutes and read the color development result of the HCG gold-labeled rapid test card, the color development result on the HCG test paper of the human serum simulation fluid sample containing CysC is positive; the color development result on the HCG test paper of the human serum simulation fluid sample containing non-CysC is negative.

[0052] Example 4

[0053] This example is based on Examples 1 to 3, and uses the CysC assay immunoturbidimetric method as a control experiment for Examples 1 to 3. The CysC assay immunoturbidimetric kit includes: a 0.03% w / v methylisothiazolinone (MIT) buffer solution (reagent 1), a latex particle coated with anti-CysC antibody (rabbit) at a concentration of less than 0.1%, and a 0.09% w / v sodium azide mixed solution (reagent 2). Required instruments: fully automatic biochemical analyzer.

[0054] The test process includes: adding 50 μL of serum main sample and 200 μL of diluent into a dilution tube to obtain a pre-diluted sample; adding 80 μL of reagent 1, 5.2 μL of pre-diluted sample and 17.4 μL of reagent 2 into a reaction tube, mixing and incubating at 37°C for 2 hours; then using an automatic biochemical analyzer to measure the absorbance of the mixture after incubation, and the test lasts for 10 minutes.

[0055] Compared with the chromogenic detection method for CysC signal transduction based on aptamer-modified HCG provided by the present invention, the method described in Example 4 requires sample pre-dilution, which increases the complexity of the detection operation; the entire test process exceeds 2 hours, while the detection time of the method of the present invention is only half of that of the control test; in addition, the control experiment test process requires the use of a fully automatic biochemical analyzer, which is expensive and bulky, making it difficult to use for self-screening and detection of patients with early renal damage.

[0056] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. A non-disease diagnosis method for chromogenic detection of cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin, characterized in that: include: The CysC-containing test sample is mixed with the enzymatic hydrolysis solution C to perform an enzymatic hydrolysis reaction to obtain an enzymatic hydrolysis reaction solution; Add blocking solution B containing BSA molecules to the reaction solution after enzymatic hydrolysis to block nonspecific binding sites and obtain a blocked mixed solution; add solution A containing aptamer-modified HCG that can specifically recognize and bind to CysC to the blocked mixed solution to react and form a reaction solution containing a stable CysC-HCG-aptamer complex; immerse the HCG gold-labeled rapid detection card in the reaction solution, and realize CysC detection of the sample to be tested through a color development reaction.

2. The non-disease diagnosis method according to claim 1, characterized in that: The volume ratio of the enzymatic hydrolysate C to the sample containing CysC to be tested is 1:10, and the enzymatic hydrolysis reaction conditions are standing at room temperature for 20 to 40 minutes.

3. The non-disease diagnosis method according to claim 1, characterized in that: The volume ratio of the blocking solution B to the blocking solution C is 8 to 15:1, and the blocking condition is incubation at room temperature for 20 to 40 minutes.

4. The method for colorimetric detection of cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin according to claim 1, characterized in that: The volume ratio of the added amount of the A solution to the C solution is 8 to 15:1, and the reaction condition for forming a stable CysC-HCG-aptamer complex is room temperature reaction for 20 to 40 minutes.

5. The non-disease diagnosis method according to claim 1, characterized in that: The HCG gold label rapid detection card is immersed in the reaction solution for 1 min to 3 min.

6. A colorimetric kit for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin, characterized in that: The color development kit comprises an enzymatic hydrolysis liquid C for enzymatically hydrolyzing a sample containing CysC to be tested, a blocking liquid B for blocking non-specific binding sites, a liquid A capable of specifically recognizing and binding to CysC, and an HCG gold-labeled rapid detection card for realizing a color development reaction; after the enzymatic hydrolysis liquid C is used to enzymatically hydrolyze the sample containing CysC to be tested, the blocking liquid B blocks the non-specific binding sites, the liquid A contains an aptamer-modified HCG capable of specifically recognizing and binding to CysC, and can specifically recognize and bind to CysC, and a stable CysC-HCG-aptamer complex is formed by reaction, the HCG gold-labeled rapid detection card receives the CysC-HCG-aptamer complex signal, and the detection result is intuitively displayed through a color development reaction.

7. The colorimetric kit for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin according to claim 6, characterized in that: The enzymolysis solution C is a papaya hydrolase solution.

8. The colorimetric kit for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin according to claim 6, characterized in that: The sealing liquid B comprises a graphene oxide dispersion and a BSA solution.

9. The colorimetric kit for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin according to claim 6, characterized in that: The solution A capable of specifically recognizing and binding to CysC includes HCG solution, sulfo-SMCC solution, and thiolated bovine serum albumin aptamer solution; the sequence of the thiolated bovine serum albumin aptamer is shown in SEIQ NO:

1.

10. Use of the chromogenic kit for cystatin C signal transduction based on aptamer-modified human chorionic gonadotropin according to any one of claims 6 to 9 in chromogenic detection of serum CysC.